Cowen

Bionano Announces Pricing of $80.0 Million Registered Offering and Concurrent Private Placement of Senior Secured Convertible Notes and Warrants

Retrieved on: 
Wednesday, October 11, 2023
Telephone, Form S-3, Attention, Finance Secretary (India), Prospectus, Cowen, Annuity, Redemption, Public access file, Genomics, Form, VWAP, Procurement, Lexington Avenue, TD, SAN, Private, Suite, Sale, Montgomery Street, Security (finance), Note, Incorporated, Stifel

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes due 2025 (the “Registered Notes”) and warrants (the “Registered Warrants”) to purchase 21,660,650 shares of its common stock in a registered offering, and (ii) $35.0 million aggregate principal amount of senior secured convertible notes due 2025 (the “Private Placement Notes” and together with the Registered Notes, the “Notes”) in a concurrent private placement, in each case, to a certain accredited investor (the “Buyer”).

Key Points: 
  • SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes due 2025 (the “Registered Notes”) and warrants (the “Registered Warrants”) to purchase 21,660,650 shares of its common stock in a registered offering, and (ii) $35.0 million aggregate principal amount of senior secured convertible notes due 2025 (the “Private Placement Notes” and together with the Registered Notes, the “Notes”) in a concurrent private placement, in each case, to a certain accredited investor (the “Buyer”).
  • The gross proceeds from the registered offering and concurrent private placement to Bionano are expected to be approximately $80.0 million, before deducting placement agent fees and offering expenses payable by Bionano.
  • The registered offering and the concurrent private placement are each contingent upon the other.
  • Bionano has also granted the Buyer an option to purchase up to an additional $25.0 million aggregate principal amount of senior secured convertible notes due 2025 (the “Additional Notes”) and warrants to purchase up to 6,768,953 shares of common stock in a subsequent private placement on substantially the same terms as the Private Placement Notes and the Registered Warrants, respectively.

Cboe Global Markets Announces New Leadership Appointments to Support Continued Global Growth

Retrieved on: 
Wednesday, October 11, 2023
Maker, Senior, Cboe Global Markets, Acquisition, Clay, NEO Exchange, Sung, Timber Hill, VIX, Risk, Cowen, Digital, CBOE, Adam, BAML, Growth, Head, DNA, Paradox Access Solutions, BofA Securities, Interactive Brokers, Bank, UBS, ATS, OneChicago, Global digital divide, Electronic trading platform, Management, Financial adviser, Data, Electronic

Catherine Clay appointed Global Head of Derivatives, a new global leadership role for the organization

Key Points: 
  • Catherine Clay appointed Global Head of Derivatives, a new global leadership role for the organization
    CHICAGO, Oct. 11, 2023 /PRNewswire/ -- Cboe Global Markets, Inc. (Cboe: CBOE), the world's leading derivatives and securities exchange network, today announced changes and new appointments to its senior leadership to further support the company's global growth strategy.
  • "Continuing the growth and expansion of our global Derivatives business presents a tremendous opportunity for Cboe and is an area where we intend to continue sharpening our focus," said Fred Tomczyk, Chief Executive Officer of Cboe Global Markets.
  • "Today's leadership appointments enable us to further leverage and expand our global footprint to deliver world-class products and services to our clients."
  • Since 2020, Adam Inzirillo held the position of Senior Vice President, Head of North American Equities at Cboe Global Markets, Inc. (Cboe).

Cboe Global Markets Announces New Leadership Appointments to Support Continued Global Growth

Retrieved on: 
Wednesday, October 11, 2023
Maker, Senior, Cboe Global Markets, Acquisition, Clay, NEO Exchange, Sung, Timber Hill, VIX, Risk, Cowen, Digital, CBOE, Adam, BAML, Growth, Head, DNA, Paradox Access Solutions, BofA Securities, Interactive Brokers, Bank, UBS, ATS, OneChicago, Global digital divide, Electronic trading platform, Management, Financial adviser, Data, Electronic

Catherine Clay appointed Global Head of Derivatives, a new global leadership role for the organization

Key Points: 
  • Catherine Clay appointed Global Head of Derivatives, a new global leadership role for the organization
    CHICAGO, Oct. 11, 2023 /PRNewswire/ -- Cboe Global Markets, Inc. (Cboe: CBOE), the world's leading derivatives and securities exchange network, today announced changes and new appointments to its senior leadership to further support the company's global growth strategy.
  • "Continuing the growth and expansion of our global Derivatives business presents a tremendous opportunity for Cboe and is an area where we intend to continue sharpening our focus," said Fred Tomczyk, Chief Executive Officer of Cboe Global Markets.
  • "Today's leadership appointments enable us to further leverage and expand our global footprint to deliver world-class products and services to our clients."
  • Since 2020, Adam Inzirillo held the position of Senior Vice President, Head of North American Equities at Cboe Global Markets, Inc. (Cboe).

Guggenheim Securities Expands Equities Division

Retrieved on: 
Thursday, September 28, 2023
Morgan Stanley, SVB Securities, University, Senior, Indian Institute of Science, Doctor of Philosophy, Jefferies, GE, Women's Institute for Science, Equity and Race, Equity, Research fellow, Cowen, General Atlantic, Research, Wells Fargo, Financial management, Guggenheim Partners, Nambi, Economics, Management, Security (finance), New York University, Guggenheim, Northeastern University

NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Dan Donner, Ronnie Habibian, Jonathan Lee, Ben Roberts, and Subbu Nambi have joined the firm to expand its Equities franchise.

Key Points: 
  • NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Dan Donner, Ronnie Habibian, Jonathan Lee, Ben Roberts, and Subbu Nambi have joined the firm to expand its Equities franchise.
  • Mr. Donner joins Guggenheim as a Senior Managing Director and Health Care Sales Specialist in the Equities Sales Group.
  • Mr. Roberts joins Guggenheim as a Managing Director in the Equities Sales Group.
  • “The additions of Dan, Ronnie, Jonathan, Ben, and Subbu to Guggenheim expands our equities capabilities, expertise, and overall platform,” said Stefano Natella, Head of Equities at Guggenheim Securities.

AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock

Retrieved on: 
Wednesday, August 16, 2023
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Janus, Citadel, Attention, Lexington Avenue, SVB Securities, AN2, TD, Telephone, Infection, Sale, Evercore, Prospectus, Equity capital markets, State Street, Oppenheimer Holdings, Form, Cowen, Therapy, Security (finance)

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the pricing of an underwritten offering of 7,777,778 shares of its common stock.

Key Points: 
  • AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the pricing of an underwritten offering of 7,777,778 shares of its common stock.
  • The shares of common stock are being sold at a price of $9.00 per share, a premium from today’s closing price.
  • The gross proceeds from the offering to AN2 are expected to be approximately $70.0 million, before deducting underwriting discounts and commissions and offering expenses.
  • The offering is expected to close on or about August 18, 2023, subject to the satisfaction of customary closing conditions.

Stephens Investment Banking Expands Technology Capabilities With New Sector Banker

Retrieved on: 
Thursday, August 3, 2023
Professional Services, Insurance, Human Resources, Finance, Consulting, Banking, Investment banking, University, University of California, Berkeley, Engineering, Berkley, Software, Multimedia, RBC Capital Markets, Business administration, Cowen, Cornell University, Master of Business Administration, Management, Science

Stephens, an independent financial services firm, has hired Peter Gant to join the firm’s Investment Banking division as a Managing Director and Head of Technology.

Key Points: 
  • Stephens, an independent financial services firm, has hired Peter Gant to join the firm’s Investment Banking division as a Managing Director and Head of Technology.
  • View the full release here: https://www.businesswire.com/news/home/20230803070119/en/
    Stephens Investment Banking Head of Technology, Managing Director Peter Gant (Photo: Business Wire)
    “Peter brings a unique and highly complementary skill set to the Stephens platform.
  • We are excited to have an investment banker of his caliber and reputation on the team,” said Matthew Marks, Executive Vice President and Head of Investment Banking.
  • “This solid foundation presents a great opportunity to further build momentum for Stephens in the technology sector.”

Vicarious Surgical Announces Pricing of Public Offering

Retrieved on: 
Thursday, August 3, 2023
Medical Devices, Health, Surgery, Other Health, General Health, Biotechnology, Morgan Stanley, Attention, Common stock, Lexington Avenue, Varick Street, Minerva Surgical, Inc. v. Hologic, Inc., Telephone, Sale, Prospectus, Form S-3, Form, Cowen, Security (finance), 2nd Floor, NYSE

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced the pricing of its underwritten public offering of 45,000,000 shares of its Class A common stock (“Common Stock”) at a price to the public of $1.00 per share.

Key Points: 
  • Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced the pricing of its underwritten public offering of 45,000,000 shares of its Class A common stock (“Common Stock”) at a price to the public of $1.00 per share.
  • In addition, Vicarious Surgical has granted the underwriters a 30-day option to purchase up to an additional 6,750,000 shares of its Common Stock.
  • The offering is expected to close on or about August 7, 2023, subject to the satisfaction of customary closing conditions.
  • Morgan Stanley & Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.

Vicarious Surgical Announces Launch of Proposed Public Offering

Retrieved on: 
Wednesday, August 2, 2023
Robotics, Medical Devices, Health, Technology, Surgery, Biotechnology, Morgan Stanley, Attention, Common stock, Lexington Avenue, Varick Street, Minerva Surgical, Inc. v. Hologic, Inc., Telephone, Sale, Prospectus, Form S-3, Form, Cowen, Security (finance), 2nd Floor, NYSE, Common

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that it has commenced an underwritten public offering of $45.0 million of shares of its Class A common stock (“Common Stock”).

Key Points: 
  • Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that it has commenced an underwritten public offering of $45.0 million of shares of its Class A common stock (“Common Stock”).
  • All of the shares of Common Stock are being offered by Vicarious Surgical.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
  • Vicarious Surgical intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, for funding of ongoing operations, including the development of our single-port surgical robot, called the Vicarious Surgical System, and other general corporate purposes.

Cardiovascular Implant Company PECA Labs Names Three New Board Members

Retrieved on: 
Tuesday, July 18, 2023
Health, Medical Devices, Cardiology, Barings Bank, Partnership, University, Raj Rajaratnam, Galleon Group, Anil Kumar, and Rajat Gupta insider trading cases, Wall Street, HUP, Heart, PwC, Yale School of Medicine, Galleon Group, Hospital of the University of Pennsylvania, Publication, Investment, Physician, PECA, UBS, Cowen, Hospital, Medtech, Cowen Inc., Management

The new board members will help guide the company as it develops and commercializes cardiovascular implants based on its novel tunable polymeric material platform.

Key Points: 
  • The new board members will help guide the company as it develops and commercializes cardiovascular implants based on its novel tunable polymeric material platform.
  • Dr. Carpenter is also a serial entrepreneur, including founding Embrella Cardiovascular, which was acquired by Edwards Lifesciences.
  • Jeffery O’Donnell, Sr. brings to PECA Labs more than 25 years of board and chief executive experience at emerging medical device companies.
  • O’Donnell founded and served as CEO for Trice Medical, and before that Embrella Cardiovascular, which was acquired by Edwards Lifesciences.

Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit

Retrieved on: 
Monday, July 3, 2023
Biotechnology, Other Health, Health, Genetics, Clinical Trials, SRPT, Sarepta, Cowen, Rare, Therapy, Event, Software, Pharmaceutical industry, Online shopping, Medical device

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at Cowen's 2nd Annual RNA Therapeutics Summit on Monday, July 10, 2023 at 11:00 a.m. E.T.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at Cowen's 2nd Annual RNA Therapeutics Summit on Monday, July 10, 2023 at 11:00 a.m. E.T.
  • The fireside chat will be held virtually.
  • The presentation will be webcast live under the Events & Presentations section of the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days.
  • Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.